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Background. Candidate gene studies have been a key approach to the genetics of schizophrenia (SCZ). However, the
results of these studies are confusing and no genes have been unequivocally implicated. The hypothesis-driven
candidate gene literature can be appraised by comparison with the results of genome-wide association studies
(GWAS).
Method. We describe the characteristics of hypothesis-driven candidate gene studies from the SZGene database, and
use pathway analysis to compare hypothesis-driven candidate genes with GWAS results from the International
Schizophrenia Consortium (ISC).
Results. SZGene contained 732 autosomal genes evaluated in 1374 studies. These genes had poor statistical power to
detect genetic eﬀects typical for human diseases, assessed only 3.7% of genes in the genome, and had low marker
densities per gene. Most genes were assessed once or twice (76.9%), providing minimal ability to evaluate consensus
across studies. The ISC studies had 89% power to detect a genetic eﬀect typical for common human diseases and
assessed 79% of known autosomal common genetic variation. Pathway analyses did not reveal enrichment of smaller
ISC p values in hypothesis-driven candidate genes, nor did a comprehensive evaluation of meta-hypotheses driving
candidate gene selection (SCZ as a disease of the synapse or neurodevelopment). The most studied hypothesis-driven
candidate genes (COMT, DRD3, DRD2, HTR2A, NRG1, BDNF, DTNBP1 and SLC6A4) had no notable ISC results.
Conclusions. We did not ﬁnd support for the idea that the hypothesis-driven candidate genes studied in the
literature are enriched for the common genetic variation involved in the etiology of SCZ. Larger samples are required
to evaluate this conclusion deﬁnitively.
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Introduction
Candidate gene studies have been a major focus in
schizophrenia (SCZ) research with the SZGene data-
base listing more than 1400 studies since 1965 (Allen
et al. 2008). By contrast, there are around 2200 PubMed
citations for ‘schizophrenia randomized controlled
trials ’. Until 5 years ago, genetic studies could inves-
tigate only an extremely small proportion of the
genome because of genotyping and cost limitations.
Investigators thus had to focus on a limited number
of genetic markers, genes and samples. In hypothesis-
driven candidate gene studies, targets were selected
based on ideas about pathophysiology or gene lo-
cation under a linkage peak (Cichon et al. 2009). For
most biomedical disorders (including SCZ), the results
of these studies were inconsistent or confusing
(Ioannidis et al. 2001). It is unclear whether this reﬂects
poor choices of candidate genes or inadequate assess-
ment (i.e. small samples or incomplete coverage of
common genetic variation).
Genotyping and cost improvements now permit
routine assessment of a million or more genetic var-
iants distributed across the genome (Beaudet &
Belmont, 2008). Genome-wide association studies
(GWAS) can extract information from most common
genetic variants in the genome either through direct
assessment of single nucleotide polymorphisms
(SNPs) or indirectly through linkage disequilibrium
(LD) between genotyped SNPs and unmeasured but
correlated genetic variants. Despite the advantages of
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genome-wide genotyping (Hindorﬀ et al. 2009), strin-
gent adjustment for multiple comparisons is required,
which necessitates the use of large sample collections.
Ten GWAS for SCZ have been published (Lencz
et al. 2007 ; O’Donovan et al. 2008 ; Shifman et al. 2008 ;
Sullivan et al. 2008 ; Kirov et al. 2009 ; Need et al. 2009 ;
Purcell et al. 2009 ; Shi et al. 2009 ; Stefansson et al. 2009 ;
Athanasiu et al. 2010). Given that some GWAS had
larger samples and more comprehensive genotyping
than typical for the candidate gene literature, GWAS
may be better placed to capture true associations than
earlier studies. Indeed, GWAS have yielded highly
signiﬁcant and replicated associations for SCZ, in-
cluding genetic variation in the major histocompati-
bility complex (MHC) region and within TCF4 and
ZNF804A (O’Donovan et al. 2008 ; Purcell et al. 2009 ;
Shi et al. 2009 ; Stefansson et al. 2009). A lack of con-
gruity has been noted between the hypothesis-driven
candidate genes for SCZ and the best ﬁndings from
GWAS. This may be typical for biomedical diseases,
where results from large GWAS infrequently corre-
spond to a priori candidate genes (www.genome.gov/
gwastudies ; Hindorﬀ et al. 2009).
For SCZ, there are multiple reasons for the lack of
overlap between GWAS and candidate gene studies.
A key possibility is that prior hypotheses about the
genetics of SCZ are incorrect. However, alternative
explanations require exploration before accepting such
an important conclusion. First, current GWAS chips
provide coverage for most but not all of the genome
(International HapMap Consortium, 2005), so par-
ticular regions and non-SNP genetic variation may be
covered poorly. Second, power may be insuﬃcient.
Although GWAS tend to have large sample sizes by
historical standards, the necessity to adjust for around
a million statistical tests could result in low power. If
that is the explanation, support for the hypotheses
underpinning previous candidate genes might be ob-
tained by amore systematic analysis of the GWAS data
for evidence for over-representation of smaller p values
than expected by chance (Holmans et al. 2009). Third,
individually rare genetic variants of strong eﬀectmight
also be missed by GWAS (although these would also
go undetected by most prior candidate gene studies).
The main purpose of this study was to compare
hypothesis-driven candidate genes for SCZ from
SZGene (Allen et al. 2008) with the largest SCZ GWAS
published to date (International Schizophrenia Con-
sortium, 2008; Purcell et al. 2009). First, we character-
ized the hypothesis-driven candidate gene studies.
Second, we conducted quantitative comparisons to
determine whether the set of hypothesis-driven can-
didate genes were either enriched for lower p values
in the International Schizophrenia Consortium (ISC)
results or contained markers with predictive power
for SCZ. Finally, we performed a qualitative compari-
son of the most studied hypothesis-driven candidate
genes with the ISC results.
Method
Hypothesis-driven candidate genes
Candidate genes for SCZ were drawn from SZGene
(Allen et al. 2008) (courtesy of Dr L. Bertram,
11 September 2009). SZGene included studies evalu-
ating associations between a genetic variant and SCZ
and published in a peer-reviewed, English-language
journal (Allen et al. 2008). Studies were identiﬁed
through PubMed, bibliographies, and tables of con-
tents. To ensure that the list was not ‘contaminated’ by
the results of GWAS, SZGene entries fromGWASwere
removed, as were genes studied only subsequent to
identiﬁcation in GWAS. As only ISC autosomal results
were available, 15 chromosome X genes were dropped.
The list of autosomal hypothesis-driven candidate
genes for SCZ contained 732 genes from 1374 studies
(see Supplementary Table S1, available online).
The purpose in creating this list was to enumerate
genes thought to be potentially etiological for SCZ by
researchers in the ﬁeld. The quality of the individual
studies was variable. However, our interest was not
in the study results per se (which can be strongly im-
pacted by quality) but rather in the choice of a gene.
Samples
The ISC study is described elsewhere (International
Schizophrenia Consortium, 2008; Purcell et al. 2009).
In brief, we studied 3322 European cases with DSM-IV
or ICD-10 SCZ and 3587 controls from seven sites. All
work was approved by institutional review boards.
After complete description of the study to the subjects,
written informed consent was obtained. Genotyping
was performed on DNA extracted from blood using
Aﬀymetrix 5.0 or 6.0 arrays. Genotypes were called
using Birdsuite (Korn et al. 2008) and imputation con-
ducted using Beagle (Browning & Browning, 2007,
2009) against the HapMap3 CEU data resulting in
1 948 385 autosomal SNPs with direct or imputed
genotypes. The primary analysis was logistic re-
gression of disease state on the imputed allele dosages
with inclusion of covariates to adjust for population
stratiﬁcation eﬀects. The Genetic Association Infor-
mation Network (GAIN) study genotyped 1230 SCZ
cases and 1136 controls of European ancestry on the
Aﬀymetrix 6.0 array (Shi et al. 2009).
Statistical analysis
We ﬁrst explored the set of hypothesis-driven candi-
date genes using a variety of descriptive approaches
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(SAS Institute Inc., 2004, 2005). Quanto was used for
power calculations (Gauderman, 2002; Gauderman &
Morrison, 2006). We used the Database for Anno-
tation, Visualization, and Integrated Discovery
(DAVID; Dennis et al. 2003 ; Sherman et al. 2007 ;
Huang et al. 2009) to characterize hypotheses about the
pathophysiology of SCZ reﬂected in the hypothesis-
driven candidate gene list. DAVID identiﬁes Gene
Ontology (GO) biological pathways (Harris et al. 2004)
with chance-corrected over-representation of a given
gene list. To account for overlap between pathways,
we used the annotation cluster feature in DAVID to
focus on higher-level clusters of similar biological
processes.
We then compared hypothesis-driven candidate
genes for SCZ with ISC GWAS results to assess
whether the hypothesis-driven candidate gene list had
over-representation of smaller ISC p values than
expected by chance. These analyses were conducted
using ALIGATOR (Holmans et al. 2009) and InRich
(Lee et al. 2011). These programs use diﬀerent algo-
rithms to assess whether GWAS ﬁndings are over-
represented for small p values with reference to a
predeﬁned set of genes (i.e. a pathway). ALIGATOR
uses permutation to account for variable numbers
of SNPs per gene, diﬀerent patterns of LD between
SNPs (within the same gene), and varying gene sizes.
We considered SZGene hypothesis-driven candidate
genes as a ‘pathway’ and used ALIGATOR to esti-
mate the probability that this list contained an over-
representation of smaller ISC GWAS p values. The ISC
GWAS results were input to ALIGATOR, which
assigned these SNPs to UCSC hg18 RefSeq genes
(Pruitt et al. 2005). We determined the signiﬁcance
threshold (generally 0.002–0.004) that designated the
top 5% of all genes as ‘signiﬁcant ’ (Holmans et al.
2009). The key statistical comparison is akin to a 2r2
table of whether a gene is in the top 5% by whether a
gene is a member of a pathway. Assessing signiﬁcance
is complex because of violation of independence
assumptions. ALIGATOR uses an SNP-based permu-
tation algorithm to create a reference distribution for
a pathway. InRich controls LD between genes by com-
paring a gene set of interest to LD-independent re-
gions. Using the same signiﬁcance thresholds as in
ALIGATOR, we identiﬁed LD-independent signiﬁcant
regions from the ISC dataset using the clump function
within PLINK (r2=0.5 over 1Mb).We then used InRich
to determine whether the candidate gene set showed
enrichment for these regions.
Polygenic score analysis was conducted as de-
scribed in the ISC GWAS paper by Purcell et al. (2009).
We used 14 811 SNPs that were genotyped in both
the ISC and SCZ GAIN samples and that mapped to
candidate genes. We made a polygenic proﬁle based
on the risk alleles within these SNPs in the ISC data,
and used this proﬁle to create a polygenic score
for each individual within the SCZ GAIN sample
(an independent target sample). We used logistic re-
gression between the score of each individual in SCZ
GAIN and their case/control status.
Results
Characteristics of hypothesis-driven candidate
gene studies of SCZ
Table 1 describes hypothesis-driven candidate genes
from SZGene (Allen et al. 2008). There were 732 auto-
somal genes from 1374 hypothesis-driven candidate
gene studies (Supplementary Table S1). These genes
were studied from one to 81 times. Most genes (563;
76.9%) were investigated in one (60.9%) or two studies
(16.0%). Although replication is important in human
genetics, there is little capacity to evaluate both false-
positive and false-negative ﬁndings. Two-thirds of
genes were assessed byf3 markers and had a median
SNP density of 15.4 kb/SNP. The median numbers of
cases (191) and controls (214) were modest.
We used pathway analysis to characterize the
hypotheses that guided candidate gene selection. The
732 hypothesis-driven candidate genes were entered
into DAVID to assess the GO biological processes to
which these genes belonged. The top four annotation
clusters consist of biological processes involved in
synaptic transmission, neuronal development and
morphogenesis, regulation of synaptic transmission,
and response to chemical stimuli (Table 1 and Sup-
plementary Table S2). The full list reﬂects a diversity
of ideas about SCZ etiology; as expected, cluster en-
richment scores were particularly strong for candidate
genes selected under the hypotheses that SCZ is a
disease of the synapse and/or a neurodevelopmental
process.
We next evaluated completeness and coverage for
the hypothesis-driven candidate genes. First, we esti-
mated statistical power to detect association. Even
for relatively large studies (i.e. samples sizes at the
90th percentiles of ncase=537 and ncontrol=628), and a
liberal correction for multiple comparisons (a=0.005,
10 markers), the power was 48% to detect genetic ef-
fects typical for GWAS of human diseases (median
genotypic relative risk of 1.28 and median minor
allele frequency of 0.29 for disease associations with
p<5r10x8) (Hindorﬀ et al. 2009). Second, we assessed
genomic coverage. The 732 hypothesis-driven candi-
date genes represent 3.7% of RefSeq autosomal genes
(Pruitt et al. 2005). Marker coverage can be assessed
only generally, but included only small proportions
of common genetic variation. Finally, of all genes
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comprising pathways in the top four DAVID anno-
tation clusters, only 6.7% had ever been studied.
Although these pathways may be overinclusive, the
main hypotheses guiding selection of hypothesis-
driven candidate genes were evaluated incompletely.
Hypothesis-driven candidate gene studies and
the ISC GWAS
The ISC GWAS had 3322 cases, 3587 controls and
1 948 385 genotyped and imputed autosomal SNPs.
The sample size was 1.36 times greater than the largest
hypothesis-driven candidate gene study. Statistical
power was 89% to detect a genetic eﬀect correspond-
ing to that typical for SNPs implicated in human dis-
ease GWAS (Hindorﬀ et al. 2009) including adjustment
for multiple comparisons (a=5r10x8). The ISC re-
ported 1 948 385 associations, which exceeds the total
associations in the SZGene database by over 180-fold.
The mean marker density over the genome was
1 SNP/1.6 kb. In comparison to HapMap (r27, phases
I+II+III), ISC markers assessed 79.0% of known
common variants present in individuals of European
ancestry either directly or indirectly with r2 o0.8.
We next investigated coverage and gene size (using
strict gene boundaries, ¡0 kb). The 732 hypothesis-
driven candidate genes were markedly larger than the
remaining 18 891 autosomal RefSeq genes (median
33.5 v. 20.5 kb, Wilcoxon p=4r10x20). Importantly,
ISC SNP densities were similar in hypothesis-driven
candidate genes in comparison to all other autosomal
genes (median 1360 v. 1379 bases/SNP, Wilcoxon
Table 1. Characteristics of hypothesis-driven candidate gene studies and the ISC GWAS
Characteristic
Candidate gene
studies ISC
Studies 1375 –
Genes (autosomal) 732 –
Markers (autosomal)
Total 6934 1 948 385
Markers per gene, median (IQR) 2 (1–5) 9 (1–34)
Genes with 1, 2 or 3 markers (%) 65.9 N.A.
Marker density per gene as
kb/SNP, median (IQR)
15.4 (4.69–46.2) 1.38 (0.69–2.47)
Sample sizea
Total subjects 412 (27–5623) 6909
Number of cases 191 (5–2434) 3322
Number of controls 214 (12–4899) 3587
Major annotation clusters from pathway
analysis (enrichment score)
Synaptic transmission 52.2 N.A.
Neuronal development and
morphogenesis
32.4 N.A.
Regulation of synaptic transmission 22.6 N.A.
Response to chemical stimuli 22.2 N.A.
Statistical powerb 0.48 0.89
Proportion of autosomal RefSeq
genes studiedc
0.037 0.902
Proportion of genes in top four
DAVID annotation clusters studied
0.067 N.A.
ISC, International Schizophrenia Consortium; GWAS, genome-wide association
studies ; SNP, single nucleotide polymorphism; IQR, interquartile range ; N.A., not
applicable ; DAVID, Database for Annotation, Visualization, and Integrated
Discovery.
a Values given as median (range) for candidate gene studies (biased due to subject
overlap across publications) or actual number for ISC.
b See text for assumptions.
c For ISC, assuming gene boundaries expanded by¡10 kb and SNP density
<20 kb/SNP.
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p=0.25). A sizable fraction of autosomal RefSeq genes
had no ISC SNPs within their boundaries (18.7%). As
expected, genes with no SNPs were markedly smaller
(median 4.1 v. 28.2 kb, Wilcoxon pB0). As the 732 SCZ
candidate genes were larger, they were signiﬁcantly
less likely to have no coverage than the remaining
RefSeq genes (10.0% v. 19.0%, p=5r10x11). Although
this generation of GWAS chips provides partial
genomic coverage of common variation, hypothesis-
driven candidate genes for SCZ had better coverage
than other RefSeq genes.
Do the ISC GWAS data support hypothesis-driven
candidate genes as signiﬁcant contributors to
SCZ risk?
There were no SNPs within the gene boundaries
(¡0 kb) for 73 hypothesis-driven candidate genes
and no SNPs within expanded gene boundaries
(¡10 kb) for 27 genes (Supplementary Table S3).
Hypothesis-driven candidate genes with no ISC
coverage were excluded from enrichment analyses. Of
they1.9 million ISC SNPs, 56 981 mapped within hy-
pothesis-driven candidate genes (¡0 kb) and 65 803
mapped within expanded gene boundaries (¡10 kb).
We assessed whether hypothesis-driven candidate
genes were over-represented for smaller ISC GWAS
p values using ALIGATOR. The central comparison
was whether there was an over-representation of the
top 5% of signiﬁcant genes in the hypothesis-driven
candidate gene list in comparison to the remaining
annotated genes. In Table 2, there was a nominally
signiﬁcant over-representation of smaller p values in
the ISC data for the full set of hypothesis-driven can-
didate genes but these values did not survive multiple
testing correction. In addition, there was no evidence
for over-representation of small ISC p values in
the most studied hypothesis-driven candidate genes
(o3 times, 23.1% of the total).
Pathway analysis can be complex in regions such
as the MHC that have extensive disequilibrium be-
tween genes (Stenzel et al. 2004). When we repeated
the ALIGATOR analysis after excluding genes in
the MHC region, there was no evidence for over-
representation of smaller p values (pB0.48), indicating
that the marginal enrichment was due to bias. We re-
peated the pathway analysis using InRich, which may
be more robust than ALIGATOR in regions of high
LD. InRich evaluates regions deﬁned by LD. We tested
the full candidate gene dataset, using the same sig-
niﬁcance thresholds as in ALIGATOR, and found no
Table 2. Testing for over-representation of smaller ISC GWAS p values in hypothesis-
driven candidate genes for SCZ and genes corresponding to major hypotheses
Gene list
Boundary
¡0 kb
Boundary
¡10 kb
SZGene hypothesis-driven candidate genes
Full set of genes 0.05 0.02
Full set, excluding MHC region 0.48 0.49
Full set, LD correction (InRich) 0.63 0.19
Genes studiedo3 times 0.19 0.45
Genes studiedo3 times, excluding MHC region 0.65 0.52
Genes in DAVID cluster 1 (synaptic transmission)
Full set of 4808 genes 1 1
Subset of 222 hypothesis-driven candidate genes 0.99 1
Genes in DAVID cluster 2 (neuronal development
and morphogenesis)
Full set of 4834 genes 1 1
Subset of 401 hypothesis-driven candidate genes 0.73 0.95
ISC, International Schizophrenia Consortium; GWAS, genome-wide association
studies ; SCZ, schizophrenia ; MHC, major histocompatibility complex ; LD, linkage
disequilibrium; DAVID, Database for Annotation, Visualization, and Integrated
Discovery.
Empirical p values (from ALIGATOR unless otherwise noted) testing for
over-representation of smaller ISC GWAS p values in a given gene list in comparison
to that expected by chance (10 000 permutations). Single nucleotide polymorphisms
(SNPs) were mapped to strict (¡0 kb) or expanded (¡10 kb) gene boundaries. SNP
thresholds to select the top 5% of genes varied from 0.002 to 0.004.
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evidence for enrichment of signiﬁcant ﬁndings in the
candidate genes (Table 2). Therefore, the pathway
analyses are consistent with the null hypothesis be-
cause all p values were non-signiﬁcant or marginal
and would not survive correction for multiple testing,
and because removal of the MHC region and analysis
with a program that corrects for LD indicates the re-
sults are a false positive resulting from extensive LD in
the MHC region.
In addition, we evaluated whether the list of his-
torical candidate genes, as a whole, were making a
signiﬁcant contribution to risk of SCZ by evaluating
the polygenic score proﬁle. This approach has pro-
vided support for an important polygenic contribution
to SCZ (Purcell et al. 2009). We created a polygenic
score proﬁle for SNPs that mapped to historical can-
didate genes using the ISC data. We then applied this
score to an independent dataset (SCZ GAIN, n=1230
cases and 1136 controls). Independent SCZ cases did
not have greater risk scores than controls based on
these historical candidate genes (p=0.92).
Many hypothesis-driven candidate genes were
selected from two overarching hypotheses : SCZ as a
synaptic or a neurodevelopmental disorder (Table 1).
These hypotheses have been incompletely assessed.
We used pathway analysis of the ISC data to assess
these hypotheses in far more detail than has been
possible previously. The set of 4808 genes that com-
prise the synaptic cluster 1 from DAVID did not show
over-representation of lower ISC p values (pB1). This
list may be overinclusive and the candidate genes
studied might be more reﬁned and appropriate to
SCZ; however, the subset of 222 cluster 1 genes in-
vestigated in a hypothesis-driven candidate gene
study did not have over-representation of smaller ISC
p values (pB1). Similarly, genes in DAVID cluster 2
(neurodevelopment) did not show enrichment for
lower ISC p values for the full set (4834 genes) or the
subset evaluated in a candidate gene study (401 genes,
all p values non-signiﬁcant).
Qualitative comparisons
Pathway analysis considers sets of genes in aggregate.
Negative aggregate results could miss true over-
representation of small p values in a small number of
hypothesis-driven candidate genes. Table 3a depicts
the ISC ﬁndings for the 10 most-studied hypothesis-
driven candidate genes. There was inadequate cover-
age for two small genes (DRD4 and APOE), and
the remainder had good SNP densities but weak
ISC results, with none surviving a liberal gene-wise
Bonferroni correction. Supplementary Fig. S2 depicts
these genes and highlights regions of conspicu-
ous attention in the literature (COMT/val58met,
DRD3/ser9gly, DRD2/Taq1A, HTR2A/T102C, NRG1/
HapICE, BDNF/val66met, DTNBP1, and SLC6A4/
HTTLPR). The ISC results do not implicate common
genetic variation in these genes. Although the region
containing SLC6A4 shows no signal, the widely
studied promoter polymorphism HTTLPR was not
directly genotyped and neighboring SNPs are in low
LD (Konneker et al. 2010).
We also investigated the 35 ISC SNPs with associ-
ations <5r10x8 and all were located at chr6 :31.58–
32.77 mb in the MHC region (Purcell et al. 2009). These
SNPs map to 10 genes (Table 3b), ﬁve of which had not
previously been the subject of a candidate gene study.
Four genes had been studied 1–5 times and one ex-
tensively (NOTCH4). The strong caveat for Table 3b is
the extensive LD in the MHC region (Supplementary
Fig. S1) ; these genome-wide signiﬁcant SNPs could
reﬂect one or a few risk variants, which may or may
not be a candidate gene.
Discussion
The main aim of this study was to evaluate the hy-
pothesis-driven candidate gene literature for SCZ with
respect to a large GWAS dataset. Hypothesis-driven
candidate gene studies have been a major approach to
the molecular etiology of SCZ. However, we now can
perform analyses of several orders of magnitude more
detailed than were possible even 5 years ago. We
wanted to determine whether the systematic in-
vestigations now allowed by GWAS supported this
body of work in aggregate and the degree to which
GWAS empirical results support the overarching
concepts that inﬂuenced candidate gene selection. We
emphasize that we did not conduct meta-analyses
of the ﬁndings of hypothesis-driven candidate gene
studies as this has been done elsewhere (Allen et al.
2008).
We acknowledge the advantages of hindsight. The
hypothesis-driven candidate gene literature, a body of
work to which the present authors have contributed,
contains numerous studies that were state of the art
when they were performed and represent consider-
able eﬀort by teams of investigators. GWAS will
undoubtedly be subject to similar scrutiny that per-
formed here for candidate gene studies. Although the
ISC study is the largest and most comprehensive of
the SCZ GWAS published to date, it was not ideal.
Statistical power was high by historical standards,
but we now know that greater power is desirable to
detect the small genotypic relative risks characteristic
of SCZ. In addition, coverage was not necessarily
‘genome-wide’, as some important regions had inad-
equate genotyping and rare genetic variation was
poorly assessed. With these caveats in mind, several
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observations of the historical candidate gene literature
emerged from our analyses.
First, hypothesis-driven candidate gene studies
had poor statistical power by contemporary stan-
dards. Even for a relatively large candidate gene study
with power-favorable multiple comparison correction,
the power would have been poor to detect the
genetic eﬀects typical for GWAS of human diseases.
As the genetic eﬀects for SCZ may be smaller than
for other human diseases (Purcell et al. 2009 ; Shi
et al. 2009 ; Stefansson et al. 2009), nearly all hypothesis-
driven candidate gene studies were underpowered.
Given what we now know about the genetic architec-
ture of SCZ, a typical candidate gene study requires
sample sizes of around 11 000 cases plus controls
for a single marker, 17 500 subjects for 10 markers,
and 24 000 subjects for 100 markers (see Sup-
plemental Methods online). Future association studies
of SCZ should use similarly realistic power calcu-
lations.
Moreover, we demonstrated that hypothesis-driven
candidate gene studies generally had poor coverage
of common genetic variation. With the resources pro-
vided by the HapMap and 1000 Genomes projects,
coupled with decreases in genotyping costs, re-
searchers can ensure that future genotyping covers the
majority of common and rare variation present in their
samples.
We were surprised to realize that most genes in the
hypothesis-driven candidate gene literature for SCZ
had been assessed only once or twice (76.9%). Given
the importance of replication in genetic studies of
Table 3a. ISC results for the 10 most studied genes from SZGene
SZGene
studies Gene Product Gene location (hg18)
ISC SNPs
(¡10 kb)
Density
(kb/SNP)
Minimum
p value
Bonferroni
correction
81 COMT Catechol-O-
methyltransferase
chr22 :18309262–18337496 43 1.1 0.042 1
71 DRD3 Dopamine receptor D3 chr3 :115330246–115380589 54 1.3 0.082 1
67 DRD2 Dopamine receptor D2 chr11 :112785526–112851211 90 1 0.14 1
57 HTR2A Serotonin receptor 2A chr13 :46305513–46368176 118 0.7 0.017 1
45 DRD4 Dopamine receptor D4 chr11 :627304–630703 1 N.A. N.A. N.A.
41 NRG1 Neuregulin 1 chr8 :31616809–32742100 1211 0.9 0.019 1
40 BDNF Brain-derived
neurotrophic factor
chr11 :27633017–27700181 39 2.2 0.0039 0.15
32 APOE Apolipoprotein E chr19 :50100878–50104490 1 N.A. N.A. N.A.
32 DTNBP1 Dystrobrevin-binding
protein 1
chr6 :15631017–15771250 140 1.1 0.026 1
32 SLC6A4 Serotonin transporter chr17 :25547505–25587080 27 2.2 0.097 1
ISC, International Schizophrenia Consortium; SNP, single nucleotide polymorphism; N.A., not applicable.
Table 3b. Genes with genome-wide signiﬁcant ISC results and studies from SZGene
SNP ISC p value
SNP location
(hg18) Gene Product
SZGene
studies
rs1150752 3.3r10x9 chr6 :32172704 TNXB Tenascin XB 4
rs3132956 3.7r10x9 chr6 :32287416 NOTCH4 Notch homolog 4 (Drosophila) 24
rs389884 9.9r10x9 chr6 :32048876 STK19 Serine/threonine kinase 19 0
rs9268208 1.2r10x8 chr6 :32388569 C6orf10 Chromosome 6 open reading frame 10 0
rs1270942 1.2r10x8 chr6 :32026839 CFB Complement factor B 5
rs3130614 2.5r10x8 chr6 :31584437 MICB MHC class I polypeptide-related sequence B 2
rs2734583 2.9r10x8 chr6 :31613459 BAT1 HLA-B associated transcript 1 1
rs3117577 3.0r10x8 chr6 :31835453 MSH5 MutS homolog 5 0
rs2187668 3.5r10x8 chr6 :32713862 HLA-DQA1 MHC, class II, DQ alpha 1 0
rs3135394 4.1r10x8 chr6 :32516475 HLA-DRA MHC, class II, DR alpha 0
ISC, International Schizophrenia Consortium; SNP, single nucleotide polymorphism; MHC, major histocompatibility
complex.
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complex traits (Chanock et al. 2007), evaluation of false
positives and false negatives is not possible. Positive
ﬁndings from one or two studies cannot be viewed as
secure (particularly given the distorting potential of
publication bias) and, conversely, negative ﬁndings
may not provide conﬁdent exclusion.
If power and coverage are low, we can anticipate
false negatives (i.e. true susceptibility loci with non-
signiﬁcant candidate gene ﬁndings). For example,
GWAS and replication eﬀorts support TCF4 as a risk
locus for SCZ (Stefansson et al. 2009). However, a TCF4
CAG repeat was studied for association with SCZ in
three studies (Vincent et al. 1999 ; Bowen et al. 2000 ;
McInnis et al. 2000). All reported negative results,
which may have led to the inappropriate exclusion of
TCF4 from consideration.
Furthermore, it is possible that the major hypoth-
eses that drove the selection of many candidate genes
are incorrect. SZGene candidate genes were selected
for many diﬀerent reasons and some resulted from
genome-wide linkage screens (most notably NRG1
and DTNBP1) (Stefansson et al. 2002 ; Straub et al.
2002). However, the ISC GWAS results did not lend
support for common variation contributing to SCZ,
either for candidate genes from the literature as a
whole or for the speciﬁc pathways from which candi-
date genes were frequently selected. For the full set of
hypothesis-driven candidate genes, there was nomi-
nally signiﬁcant support for an over-representation of
small ISC p values. However, the eﬀect was marginal,
and the results were not signiﬁcant when corrected
for potential bias caused by LD between genes. We
found no support for an aggregate eﬀect of hypoth-
esis-driven candidate genes contributing to SCZ risk
using a risk proﬁle generated from the SNPs within
these genes. This pattern of results is not consistent
with robust or notable collective contribution of com-
mon variation within the hypothesis-driven candidate
genes to SCZ based on the ISC data. However, it
is possible that subsets of the heterogeneous list of
historical candidate genes are enriched for smaller ISC
p values. We thus tested the two overarching ‘meta-
hypotheses ’ that have been highly inﬂuential : notions
of SCZ as a disease of the synapse and as a neuro-
developmental disease. To our knowledge, these two
larger-scale ideas have not been tested for empirical
support in aggregate. We found no evidence to sup-
port a genetic basis for these two hypotheses in per-
haps the most comprehensive analysis yet conducted.
In addition, we speciﬁcally evaluated eight of the
10 most studied historical candidate genes and the
ISC GWAS results provide no support for common
genetic variation associated with SCZ. We note that
the strongest ISC GWAS ﬁndings were in the MHC
region. Genes from the expanded MHC region do
appear in the hypothesis-driven candidate gene
literature. Most notably, NOTCH4 had genome-wide
signiﬁcant SNPs in the ISC data and was highly
studied (24 times ; both positive and negative studies)
in the candidate gene literature. However, given the
high LD in the region (Supplementary Table S1), we
cannot localize the MHC signal more speciﬁcally. We
cannot therefore either directly validate or exclude
NOTCH4 as being involved in SCZ susceptibility.
Finally, more generally, there are now numerous
guidelines for candidate gene studies (Chanock et al.
2007 ; Pearson &Manolio, 2008). If these guidelines are
followed at all stages of the scientiﬁc process (from
study design through review), the published literature
will better reﬂect the genetic architecture of SCZ.
No single study can disprove a meta-hypothesis
in psychiatry, and our conclusions are bounded by
the statistical power of the ISC sample. However, it is
notable that the ISC GWAS results do not support
enrichment of SCZ susceptibility loci within the can-
didate genes. These results suggest, but do not prove,
that many traditional ideas about the genetic basis of
SCZ may be incorrect. Indeed, the singular advantage
of genomic surveys is that they are unbiased by prior
knowledge and can yield novel and unexpected ﬁnd-
ings. Given current knowledge of the genetic archi-
tecture of SCZ and the capacity to assess common and
rare variations across the genome, it is possible that
the next few years will lead to marked changes in
major hypotheses about the genetic basis of SCZ.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
psm).
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